Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Through the acquisition, CASI gains global rights to the Cleave's clinical asset, CB-5339 tosylate, an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, in patients with acute myeloid leukemia and myelodysplastic syn...
Product Name : CB-5339
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Eikon Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets
Details : Through the acquisition, Eikon gains Cleave’s preclinical assets, including a large chemical library spanning multiple targets in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Eikon Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the terms of the agreement, Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets.
Product Name : CB-5339
Product Type : Other Small Molecule
Upfront Cash : $5.5 million
August 03, 2021
Details : First patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS).
Product Name : CB-5339
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2020
Reset All
